Lipoprotein(a) and Cardiovascular Disease in Chinese Population

Li, Jianjun; Ma, Changsheng; Zhao, Dong; Yan, Xiao-Wei; Chen, Hong; Li, Yong; Yuan, Zuyi; Zhang, Ruiyan; Zhao, Shui‐Ping; Li, Guoping; Liang, Chieh Kai; Dong, Yugang; Chen, Zhenyue; Peng, Daoquan; Tang, Yi‐Da; Wang, Fang; Zhou, Zhou; Sun, Yihong; Liu, Jing; Guo, Yuan‐Lin; Yuan, Hui; Wu, Na‐Qiong; Zhu, Ye

doi:10.1016/j.jacasi.2022.08.015

Cited by 29 publications

(22 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients were divided into two groups: low Lp(a) group [LP(a) < 30 mg/dL] and high Lp(a) group [LP(a) ≥ 30 mg/dL]. We chose 30 mg/dL as the cut‐off value of LP(a) according to research evidence from the Chinese population and previous studies from the Asian population 8–10 . Considering the potential influence of diabetic status and gender on LP(a) serum level, when we discussed the association of LP(a) and severity of PAD, we grouped the patients according to their gender and history of diabetes mellitus (DM).…”

Section: Methodsmentioning

confidence: 99%

Association between lipoprotein(a) and peripheral arterial disease in coronary artery bypass grafting patients

Gao

Liu

et al. 2023

Clinical Cardiology

View full text Add to dashboard Cite

Objective Peripheral arterial disease (PAD) affects a large population and is associated with various adverse clinical outcomes. Lipoprotein(a) has proatherogenic properties and is associated with PAD incidence and severity. The aim of this study is to explore the association between LP(a) and PAD in coronary artery bypass grafting (CABG) patients. Methods A total of 1001 patients were included and divided into two groups: low Lp(a) group [LP(a) < 30 mg/dL] and high Lp(a) group [LP(a) ≥ 30 mg/dL]. A comparison of PAD incidence diagnosed by ultrasound was made between the groups. Multivariate logistic regression was conducted to explore the risk factors for PAD. During the analysis, the influence of diabetes mellitus (DM) and gender on LP(a) serum level was taken into consideration. Results DM history (odds ratio [OR], 2.330, p = .000 for males; OR, 2.499, p = .002 for females) and age (OR, 1.101, p = .000 for males; OR, 1.071, p = .001 for females) were risk factors for PAD. LP(a) ≥ 30 mg/dL was a risk factor for PAD only in female patients (OR, 2.589, p = .003), while smoking history was a risk factor only in male patients (OR, 1.928, p = .000). LP(a) level was not associated with PAD severity in DM patients of both gender. As for female patients without DM, PAD was more severe in the high LP(a) group. Conclusions In CABG patients, DM history and age were risk factors for PAD. But a high level of LP(a) was a significant risk factor only in female patients. In addition, we are the first to propose a gender deviation in the correlation between LP(a) serum level and severity of PAD diagnosed by ultrasound.

show abstract

Section: Methodsmentioning

confidence: 99%

Association between lipoprotein(a) and peripheral arterial disease in coronary artery bypass grafting patients

Gao

Liu

et al. 2023

Clinical Cardiology

View full text Add to dashboard Cite

show abstract

“…In patients with CVD and type 2 diabetes mellitus, the risk of CVD associated with Lp(a) might be further increased. 4 | TARGET POPULATION FOR LP(a)…”

Section: Atherogenic Evidence Of Lp(a) In the Chinese Populationmentioning

confidence: 99%

“…The expert panel of the Beijing Heart Society has extended the systematic knowledge regarding Lp(a) beyond integrating the current global knowledge of Lp(a) and summarizing the evidence from Chinese populations. The scientific statement from Beijing Heart Society suggests key points for managing Lp(a) in Chinese populations for reference in clinical practice [4].…”

Section: Introductionmentioning

confidence: 99%

Focus on lipoprotein(a): The time is now

Lin,

Yang,

Zhou

2023

iLABMED

Self Cite

View full text Add to dashboard Cite

“…Lp(a) is an independent risk factor for cardiovascular disease. ( 38 ) Lp(a) tends to oxidize after entering the blood vessel wall, producing pro-inflammatory oxLDL. ( 39 ) However, the drugs that can effectively reduce Lp(a) are still in the research process.…”

Section: Discussionmentioning

confidence: 99%

Acute effect of proprotein convertase subtilisin/kexin type 9 inhibitor on oxidized low-density lipoprotein and lipid profile in patients at cardiovascular risk

Li,

Sun,

et al. 2023

J. Clin. Biochem. Nutr.

View full text Add to dashboard Cite

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a new class of potent lipid-lowering drugs. Oxidized low-density lipoprotein (ox-LDL) is the key pathogenic factor leading to atherosclerosis. However, its effect on ox-LDL levels has not been clinically reported. The clinical data of 290 very high-risk atherosclerotic cardiovascular disease (ASCVD) patients diagnosed in the First Affiliated Hospital of Zhengzhou University from May 2022 to October 2022 were collected retrospectively. According to whether evolocumab (a PCSK9 inhibitor) was used after percutaneous coronary intervention (PCI), they were divided into evolocumab group (153 cases) and statin monotherapy group (137 cases). At hospital admission, ox-LDL, total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoproteinA1 (apoA1), apolipoprotein B-100 (apoB), lipoprotein (a) [Lp(a)], and high-sensitivity reactive protein (hs-CRP) levels were collected and used as baseline data. After two weeks of treatment, ox-LDL in the evolocumab group and statin monotherapy group were significantly lower than those before treatment ( p <0.05). The decrease of ox-LDL in the evolocumab group was more than in the stain monotherapy group ( p <0.05). In conclusion, PCSK9 inhibitors reduce ox-LDL levels in very high-risk ASCVD patients in a short time.

show abstract

Lipoprotein(a) and Cardiovascular Disease in Chinese Population

Cited by 29 publications

References 75 publications

Association between lipoprotein(a) and peripheral arterial disease in coronary artery bypass grafting patients

Association between lipoprotein(a) and peripheral arterial disease in coronary artery bypass grafting patients

Focus on lipoprotein(a): The time is now

Acute effect of proprotein convertase subtilisin/kexin type 9 inhibitor on oxidized low-density lipoprotein and lipid profile in patients at cardiovascular risk

Contact Info

Product

Resources

About